Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy – a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol

Alice Boilève 1*, Aline Maillard 2,3, Mathilde Wagner 4, Clarisse Dromain 5, Christophe Laurent 6, Eric Dupont Bierre 7, Samuel Le Sourd 8, Franck Audemard 9, Ayhan Ulusakarya 10, Veronique Guerin-Meyer 11, Denis Smisth 6, Veronica Pezzella 12, Thierry De Baere 13, Diane Goere 14, Maximiliano Gelli 15, Julien Taieb 16 and Valérie Boige 1

Abstract

Background: Approximately 40% of colorectal cancer patients will develop colorectal liver metastases (CRLM). The most effective approach to increase long-term survival is CRLM complete resection. Unfortunately, only 10–15% of CRLM are initially considered resectable. The objective response rates (ORR) after current first-line systemic chemotherapy (sys-CT) regimens range from 40 to 80% and complete resection rates (CRR) range from 25 to 50% in patients with initially unresectable CRLM. When CRLM patients are not amenable to complete resection after induction of sys-CT, ORRs obtained with second-line sys-CT are much lower (between 10 and 30%) and consequently CRRs are also low (< 10%). Hepatic arterial infusion (HAI) oxaliplatin may represent a salvage therapy in patients with CRLM unresectable after one or more sys-CT regimens with ORRs and CRRs up to 60 and 30%, respectively. This study is designed to evaluate the efficacy of an intensification strategy based on HAI oxaliplatin combined with sys-CT as a salvage treatment in patients with CRLM unresectable after at least 2 months of first-line induction sys-CT.

(Continued on next page)
Background and rationale
Secondary resection of colorectal liver metastases after systemic chemotherapy
Approximately 40% of colorectal cancer (CRC) patients will be diagnosed with colorectal liver metastases (CRLM), either at primary tumor diagnosis (20%) or during disease progression (20%) [1–4]. The only chance of cure and the most effective approach to increase long-term survival is complete CRLM resection, with a 5-year overall survival (OS) rates between 30 and 40% [5–7]. Unfortunately, only 10–15% of CRLM are initially considered easily resectable. Therefore, induction systemic chemotherapy (sys-CT) to shrink the tumor is often required to convert unresectable to resectable CRLM allowing resection with curative intent and a favorable long-term prognosis, with a 33% 5-year survival rate [8].

In selected patients with liver-only metastasis, complete resection (or ablation) rate (CRR) is reported to be linearly proportional to the objective response rate (ORR) [9]. Current first-line sys-CT regimens combining fluorouracil and oxaliplatin, with or without irinotecan, associated with targeted therapies (anti-EGFR or antiangiogenic antibodies) achieve ORR ranging from 40 to 80% [7] with (R0-R1) CRR ranging from 25 to 50% in patients with initially unresectable CRLM [10–12].

When CRLM patients are not amenable to resection after induction sys-CT, ORRs obtained with second-line sys-CT are much lower, between 10 and 30% and consequently CRRs are expected to be low (<10%) in this population of patients [9]. The CRRs following modern second-line sys-CT regimens have not been prospectively assessed. In a retrospective post-chemotherapy hepatectomy study, published by Adam et al. [10], only 7% of patients underwent curative hepatectomy after second-line treatment.

Hepatic arterial infusion of chemotherapeutic agents
Since liver metastases mainly receive blood supply from the hepatic artery whereas normal liver tissue is primarily perfused by the portal vein, hepatic arterial infusion (HAI) was developed to increase the local concentration of cytotoxic agents to liver metastases. As a result, HAI achieved significantly higher tumor response rates with limited systemic toxicity compared to sys-CT in patients with unresectable CRLM [13–22]. A significant impact on OS has been inconsistently observed in previous randomized trials with HAI fluorodeoxyuridine (FUDR) or 5-Fluorouracil (5-FU), mainly due to extra-hepatic disease and/or the design of these studies that allowed cross-over of HAI [23].

Several chemotherapeutic agents have been administered via HAI to treat CRLM [24]. FUDR is mainly used for HAI because of its short half-life (<10 min) and extensive extraction/metabolism during the first liver passage (94–99%) [21, 24, 25]. However, the biliary related-toxicity and the inconvenience of a surgically implanted port requiring a 2-week continuous infusion are the main limitations of HAI FUDR. To improve the tolerance and efficacy of HAI FUDR, the addition of steroid agents in the hepatic artery (in order to reduce biliary toxicity) and addition of “modern” concomitant systemic cytotoxic drugs (such as irinotecan or oxaliplatin) has been developed [26, 27].

Alternatively, more recent HAI chemotherapeutic agents can be used, of which oxaliplatin is one of the most important. We reported that HAI oxaliplatin accumulates in liver metastases with a concentration ratio tumor/normal parenchyma of 4.3 with a significant decrease of total platinum and filtrable platinum [28]. This suggests an improved benefit of the HAI route in terms of tolerance (e.g., reduced peripheral neuropathy and
hematological toxicity) and efficacy. HAI oxaliplatin also presented a liver extraction ratio of 0.47 [29] and is more convenient than FUDR (2-h HAI of oxaliplatin repeated every 2 weeks; continuous HAI of FUDR during 14 days repeated every 4 to 5 weeks). In addition, we reported that HAI oxaliplatin overcomes resistance to prior intravenous (IV) oxaliplatin in heavily pretreated patients [30].

Our previous multicentric phase II trial showed that HAI oxaliplatin and systemic 5-FU-folinic acid (LV5FU2 schedule) induced a response rate of 64% (95% confident interval: 44–81%) with a median survival of 27 months (survival rates were 82% at 1 year and 63% at 2 years) in 28 patients with unresectable CRLM in the first-line \( (n = 7) \) or second-line \( (n = 21) \) settings [30]. The toxicity was manageable including mostly grade 3 \( (n = 8) \) and grade 4 \( (n = 2) \) neutropenia, as well as severe abdominal pain during oxaliplatin administration \( (n = 6) \).

In a retrospective study, we showed that adding HAI oxaliplatin to systemic 5-FU in 87 patients (78% after one or more lines of sys-CT) successfully converted unresectable to resectable CRLM in 24% of patients, with a complete pathological response rate of 19% in patients who underwent surgery [31].

Lastly, the OPTILIV prospective multicenter phase II study assessed HAI triplet chemotherapy (5-FU, oxaliplatin, and irinotecan) combined with systemic cetuximab in 64 heavily pretreated patients with KRAS wild-type CRC with unresectable CRLM after at least one first-line sys-CT, of which more than 50% had received > 2 lines of chemotherapy [32]. The ORR was 40.6% and the CRR (R0-R1) was 29% [32].

To date, no randomized study has compared HAI combined with sys-CT to standard systemic regimens in patients with CRLM still unresectable after ‘modern’ induction sys-CT. Furthermore, we have shown that the development of percutaneous hepatic arterial catheter insertion under radiology guidance have greatly increased the feasibility, functionality, and safety of HAI chemotherapy [33, 34]. We have thus designed a study to evaluate the efficacy of an intensification strategy based on HAI oxaliplatin combined with sys-CT as a salvage treatment in patients with CRLM unresectable after at least 2 months of induction sys-CT.

Methods
This study is designed as a multicenter, randomized, comparative phase II trial. The study flow-chart is detailed on Fig. 1.

Study objectives and endpoints

Primary objective
The primary objective is to assess the efficacy of HAI in terms of complete (R0-R1) resection (or ablation) rate (CRR) in patients with liver-only CRLM not amenable to curative-intent resection (and/or ablation) after at least 2 months of induction sys-CT. Randomized patients will receive either chemotherapy intensification combining HAI oxaliplatin plus systemic FOLFIRI and targeted therapy (i.e. anti-EGFR antibody or bevacizumab) or conventional sys-CT and targeted therapy (i.e. anti-EGFR or antiangiogenic antibody).

Secondary objectives
The secondary objectives include the efficacy of combined HAI and sys-CT on OS, progression-free survival (PFS; overall, hepatic, and extrahepatic), ORR, and depth of response (DoR). For this study, OS is defined by the delay between randomization and the occurrence of death due to any cause, or the date of last follow-up in patients alive. PFS is defined by the delay between randomization and the occurrence of the first progression whatever its time of occurrence or death, or the date of last follow-up in patients alive without progression. Progression will be defined according to response evaluation criteria in solid tumors (RECIST) v1.1. For hepatic PFS, only hepatic progressions are taken into account, patients with extra-hepatic progression are censored at the time of this progression. Extra-hepatic PFS is the opposite, only extra-hepatic progressions are taken into account, patients with hepatic progression are censored at the time of this progression. ORR is defined as the best overall response according to RECIST v1.1 evaluated by computed tomography of thorax, abdomen and pelvis (CT-TAP) scan or magnetic resonance imaging (MRI) every 8 weeks. DoR is defined as the relative change in the sum of longest diameters of RECIST target lesions at the nadir, in the absence of new lesions or progression of non-target lesions, as compared to baseline.

The feasibility of treatments, with the proportion of patients receiving ≥4 cycles of HAI oxaliplatin (experimental arm only), the dose-intensity of oxaliplatin and other systemic cytotoxic/targeted agents received, and the proportion of patients receiving ≥4 cycles of sys-CT (both arms) will also be evaluated.

Finally, the tolerance will be carefully considered using the National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0 to evaluate the toxicity of HAI and sys-CT, including HAI catheter-related complications and treatment related mortality.

Ancillary objectives
The SULTAN study also encompasses ancillary evaluation of the duration of objectives and stable responses, the relative change in the sum of longest diameters of RECIST target lesions at week 8 compared to baseline, and the complete pathological response in case of CRLM resection. For the patients with curative surgery, time without any chemotherapy...
in both arms in the period between R0/R1 surgery and new chemotherapy for recurrence or date of last follow-up in the absence of recurrence will be evaluated. The European Organization for Research and Treatment of Cancer (EORTC) core quality of life questionnaire (QLQ) EORTC QLQ-C30 associated with the Liver colorectal metastasis Module QLQ-LMC21 will be used to evaluate the quality of life of patients included in this study [18].

Study population

Inclusion criteria

Eligible patients should have a histologically confirmed stage IV CRC with a radiologic or histologic proof of CRLM not amenable to a curative intent-treatment after at least 2 months and no more than 6 months of first-line induction sys-CT with oxaliplatin and/or irinotecan combined with a fluoropyrimidine and a targeted therapy. Unresectability of the CRLM will be confirmed by a centralized multidisciplinary expert panel according the following criteria: upfront R0/R1 resection of all CRLM (that leaves at least two adequately perfused and drained segments) not possible, and/or metastases in contact with major vessels of the remnant liver which would require resection of the vessel for an R0 resection (i.e., tumor involvement of main portal right and left portal veins, of the three main hepatic veins, or of the retrohepatic vena cava), and/or documented progressive disease on imaging (according to the RECIST v1.1 criteria) or doubling of serum levels of tumor markers following ≥2 months of induction chemotherapy. Patients must be 18 years or older, have a good general health status, normal liver, kidney, cardiac, hematologic, and coagulation functions. Patients should
also agree to contraceptive methods, be affiliated to a social security regimen, and provide a signed informed consent form before study entry (Table 1).

**Exclusion criteria**

Patients eligible for curative-intent treatment of CRLM, with definitive anatomical contraindications to complete surgical resection, with extrahepatic metastasis or with disease progression after FOLFOXIRI/FOLFIRINOX treatment are not eligible for the SULTAN study. Other criteria comprise patients with contraindications to study drugs (contraindication limited to targeted therapy are allowed), concomitant medications/comorbidities that may prevent the patient from receiving study drugs.

### Table 1 List of eligibility criteria of the SULTAN study

| Inclusion criteria                                                                 | Exclusion criteria                                                                 |
|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| 1. Histologically confirmed CRC, and radiologic or histologic proof of CRLM not amenable to a curative intent-treatment after 2 months to 6 months of first-line induction chemotherapy | 1. Patient eligible for curative-intent treatment of CRLM (i.e. resection and/or thermoablation), according to local multidisciplinary team and/or central review |
| 2. First-line chemotherapy with oxaliplatin and/or irinotecan combined with a fluoropyrimidine and a targeted therapy (e.g., anti-EGFR or antiangiogenic antibody) for metastatic disease patients ending their adjuvant chemotherapy after primary tumor resection since more than 6 months should also have received first-line chemotherapy for metastatic disease | 2. Definitive anatomical contraindication to complete surgical resection: a. More than two lesions in all liver segments b. Bilobar liver metastasis and more than three lesions > 3 cm in the hepatic lobe the least affected (i.e. the future remnant liver) c. Bilobar liver metastasis and disease liver extend > 50% |
| 3. Unresectability of the CRLM will be confirmed by a centralized multidisciplinary expert panel (composed of surgeons, radiologists, interventional radiologists and medical oncologists). The panel will review the CT scan and MRI of the patients (weekly web conference) Non-resectability criteria (one of the following criteria): ✓ Upfront R0/R1 resection of all CRLM (that leaves at least two adequately perfused and drained segments) is not possible ✓ and/or metastases in contact with major vessels of the remnant liver which would require resection of the vessel for an R0 resection (i.e., tumor involvement of main portal right and left portal veins, of the three main hepatic veins, or of the retrohepatic vena cava) ✓ and/or documented progressive disease on imaging (according to the RECIST v1.1 criteria) or doubling of serum levels of carcinoembryonic antigen (CEA) or CA 19.9 following ≥2 months of induction chemotherapy | 3. Extrahepatic metastases (except ≤3 lung nodules < 10 mm deemed amenable to curative-intent resection/thermoablation and non-rectected primary tumor with no or mild symptoms) |
| 4. At least one measurable liver metastasis according to the RECIST v1.1 criteria | 4. Patient with concomindication for trial drugs; contraindication limited to targeted therapy (e.g., anti-EGFR or antiangiogenic antibody) are allowed |
| 5. Age ≥ 18 years                                                                 | 5. Disease progression after FOLFIRI/FOLFIRINOX |
| 6. ECOG performance status 0–1                                                   | 6. Sensory neuropathy ≥ grade 2 (NCI-CTAE v4.0) |
| 7. Normal liver function: bilirubin < 1.5 x upper limit of normal values (ULN), aminotransferases < 5 ULN, alkaline phosphatase < 5 ULN | 7. If patients received bevacizumab, following non-inclusion criteria must be respected: a. Proteinuria > 1 g |
| 8. International normalized ratio (INR) < 1.5 ULN                                 | b. Gastro-intestinal fistulae or perforation |
| 9. Neutrophils > 1500/mm³, platelets > 100,000/mm³, hemoglobin > 9 g/dL (transfusion allowed) | c. Hypersensitivity to Chinese hamster ovary cell products or other human recombinant antibody |
| 10. Calculated creatinine clearance > 50 mL/min (Cockcroft and Gault formula)    | d. Major surgery in the last 28 days |
| 11. Informed consent signed by the patient or his/her legal representative       | 8. If patients received panitumumab, following non-inclusion criteria must be respected: a. Interstitial lung disease |
| 12. Patient affiliated to a social security regimen                               | b. Pulmonary fibrosis |
| 13. Potentially reproductive patients must agree to use an effective contraceptive method or practice adequate methods of birth control or practice complete abstinence while on treatment, and for at least 6 months after the last dose of study drug | 9. Significant chronic liver disease (resulting in portal hypertension and/or liver failure) |
|                                                                                 | 10. Allergy to contrast media that cannot be managed with standard care |
|                                                                                 | 11. Previous organ transplantation, HTx or other immunodeficiency syndromes |
|                                                                                 | 12. Concomitant or past history of cancer within 5 years prior to entry into the trial (except treated basal-cell skin cancer or in situ carcinoma of the cervix) |
|                                                                                 | 13. Patients with clinically significant active heart disease or myocardial infarction in the last 6 months |
|                                                                                 | 14. Concomitant medications/comorbidities that may prevent the patient from receiving study treatments as uncontrolled intercurrent illness (for instance: active infection, active inflammatory disorders, inflammatory bowel disease, intestinal obstruction, uncontrolled hypertenstion systolic > 15 and diastolic > 9, symptomatic congestive heart failure…) |
|                                                                                 | 15. Ionic disorders as: a. Kalemia ≤1 x ULN  b. Magnesemia < 0.5 mmol/L  c. Calcium <2 mmol/L  d. Major surgery in the last 28 days |
|                                                                                 | 16. Patient with a dihydropterymidine dehydrogenase deficiency (DPD): the test should be done for all patients before first 5-FU administration, according recommendations about the high risk of no testing DPD in patient before 5-FU administration |
|                                                                                 | 17. QT/QTc > 450 msec (men) and > 470 msec (women) |
|                                                                                 | 18. Concomitant intake of St. John's wort |
|                                                                                 | 19. Patient already included in another clinical trial with an experimental treatment |
|                                                                                 | 20. Pregnancy or lactation |
|                                                                                 | 21. Patients deprived of liberty or under guardianship |
|                                                                                 | 22. Patients unable to undergo medical monitoring for geographical, social or psychological reasons |
treatments, concomitant intake of St. John’s wort, or allergy to contrast media that cannot be managed with standard care. Specific contraindications to the administration of bevacizumab or panitumumab are also considered exclusion criteria. Patients with sensory neuropathy [≥ grade 2 (NCI-CTAE v.4.0), significant chronic liver disease, history of cancer within 5 years prior to entry into the study (other than adequately treated basal-cell skin cancer or in situ carcinoma of the cervix), clinically significant active heart disease or myocardial infarction in the last 6 months, risk of developing ventricular arrhythmia, previous organ transplantation, HIV or other immunodeficiency syndromes, or dihydropyrimidine dehydrogenase deficiency cannot be included in the study. Patients should not be pregnant or breast-feeding, already included in another clinical study with an experimental molecule, deprived of liberty or under guardianship, or unable to undergo medical monitoring test for geographical, social or psychological reasons (Table 1).

**Randomization**
Randomization will be performed using the module of the eCRF / Ennov Clinical® software and will be stratified using minimization method according to the following factors:

- Prior adjuvant or first-line induction oxaliplatin-based chemotherapy
- Tumor response to induction sys-CT at the time of patient inclusion (objective response versus stable disease versus progressive disease)
- Center

**Treatment schedule**
Patients will be randomly assigned in a 1:1 ratio to the experimental arm (Arm A) or the control arm (Arm B).

**Arm a (experimental arm)**
HAI oxaliplatin combined with systemic FOLFIRI plus targeted therapy every 2 weeks. Patients will receive 2-h HAI oxaliplatin 100 mg/m², combined with systemic modified FOLFIRI regimen without 5-FU bolus (1.5-h IV Irinotecan 180 mg/m², no IV 5-FU bolus, 2-h IV leucovorin 400 mg/m² [200 mg/m² in 2 h for racemic mixture if L-folinic acid], followed by 46-h IV 5-FU 2400 mg/m²) plus 2-h IV cetuximab 500 mg/m² or 1-h IV panitumumab 6 mg/kg or 30-min IV bevacizumab 5 mg/kg according to RAS status and prior response/tolerance to induction sys-CT.

**Arm B (control arm)**
Sys-CT, combined with a targeted therapy (i.e. anti-EGFR or antiangiogenic antibody), defined by the investigator before randomization according to response to prior induction chemotherapy, toxicity and duration of the induction chemotherapy, RAS status and current guidelines/standard of care [35, 36]. In order to minimize the heterogeneity between the two treatment arms, priority should be given to a biweekly regimens compatible with tumor response evaluation each 8 weeks, including FOLFIRI, FOLFOX, FOLFIRINOX, or LV5FU2 combined with a targeted therapy (i.e. 3 weekly schedules of XELOX or XELIRI are not authorized). The choice of treatment regimen in the control arm will be discussed with the expert panel before randomization for each patient.

In the control arm, the intensification of the induction sys-CT, if needed, will be done at the time of randomization and not as a second step following a less intensive treatment.

In both arms, treatment will be administrated until disease progression, limiting toxicity, or CRLM surgery. A 3-month adjuvant chemotherapy is recommended in case of curative-intent CRLM resection: the regimen administered before surgery, but without the targeted therapy, will be used whenever possible in the experimental arm, and FOLFOX will be used in the control arm. Three months of adjuvant chemotherapy with LV5FU2 or FOLFIRI (especially in case of objective tumor response under preoperative FOLFIRI regimen) can be discussed in case of limiting neuropathy or disease progression after FOLFOX, respectively.

The HAI catheter will be placed before initiating treatment, percutaneously by interventional radiologist under fluoroscopic monitoring in order to allow perfusion of the full liver volume through a single catheter linked to an implantable port [33], or surgically in case of planned laparotomy. A digital subtracted angiography during injection of contrast medium through the HAI catheter port will be systematically obtained before treatment initiation, and then every two courses of HAI. HAI will be delivered if the control angiogram confirms the patency of the catheter and perfusion of the entire liver without any extrahepatic perfusion or leak. Only physicians and nurses familiar with the HAI technique will perform the HAI chemotherapy.

**Assessments and follow-up**
During treatment period, a physical, biological, and paraclinical examination will be performed every 2 weeks (Table 2 and Fig. 1). In the experimental arm, a verification of the port-catheter will be performed by angiogram (or angioscintigraphy) prior to treatment initiation with HAI oxaliplatin then every 28 days (more frequently upon request if port-catheter dysfunction is suspected) during the treatment phase.

Every 8 weeks, a CT-TAP scans (and liver MRI if needed) will be performed and patients will be asked to complete the quality of life questionnaires.
| VISITS | Screening after 2 to 6 months of CT | Baseline Within 21 days before randomization | Treatment period | End of treatment 2 to 4 weeks after the last administration of the study treatment | Follow-up Every 2 months for minimum 12 months to 48 months after randomization |
|--------|-----------------------------------|---------------------------------------------|-----------------|-----------------------------------------------------------------|--------------------------------------------------------------------------------|
|        |                                   | Every 2 weeks                              | Every 28 days   | Every 8 weeks                                                   |                                                                              |

**Inclusion / non-inclusion criteria**
- Signed informed consent form (x)

**Randomization (R)** (x)
- Medical history and prior treatment history (x)
- Central review (verification on the unresectability of CRLM) (x)

**PHYSICAL EXAMINATION**
- Complete clinical examination & vital signs (x)
- Performance status (ECOG) (x)
- Toxocities/ adverse events/ signs and symptoms (x)
- Concomitant treatments (x)

**PARACLINICAL EXAMINATION**
- Thoraco-abdomino and pelvic CT scan and/or liver MRI (x)
- Angiogram or scintigraphic hepatic infusion in the experimental arm (x)
- ECG (x)

**BIOLOGICAL TESTS**
- Hematology (neutrophils, platelets, haemoglobin), (x)
- Biochemistry (including kalemia, magnesemia, calcemia, glycemia) (x)
- Liver function (alkaline phosphatase, total and conjugated bilirubin, AST, ALT, LDH) (x)
- Albuminemia, Protidemia (x)
- INR (x)
- Renal function (creatininemia, urea, calculated creatine clearance) (x)
- Proteinuria (x)
- Pregnancy test (x)
- Tumor marker: CEA + CA 19.9 (x)

**QUALITY of LIFE QUESTIONNARY**
- QLQ-C30 + QLQ-LMC21 (x)

---

*within 7 days of randomization for baseline assessment and to be realized before and after oxaliplatin intravenous or intrahepatic arterial infusion (HAI); after randomization; *after randomization and before the start of intra-arterial oxaliplatin; ^at least every 28 days during the treatment phase, more often if needed, ^only for patients who received bevacizumab, ~Until progression for a maximum 2 years
A final evaluation will be realized within the 2 to 4 weeks following the last administration of the study treatment with physical and biological examinations.

In absence of progression, follow-up assessment will be performed every 2 months during minimum 12 months to 48 months after the randomization. For each visit, the assessments described in Table 2 will be performed. After progression, follow-up will only be performed every 2 months for a maximum of 48 months after the randomization and will consist in getting data about overall survival.

**Statistical considerations**

**Required number of patients**

Based on the CRR as the primary objective of this comparative randomized multicenter phase II study, the hypotheses are the following:

- P0: conversion to resectability rate (i.e. complete (R0-R1) resection rate = CRR) in the control arm = 10%
- P1: conversion to resectability rate in the experimental arm = 30%

With these hypothesis and to have a 80% power (beta risk = 20%) and an alpha risk of 5% (two-sided Chi² test), a total of 124 evaluable patients will be required (62 in each arm). Taking into account non-evaluable patients (primary failure of the HAI procedure in the experimental arm, patients receiving less than 4 cycles of HAI oxaliplatin) (at least 10%), additional patients will have to be randomized to ensure a sufficient number of evaluable patients in the HAI arm for the per-protocol analysis. The rate of patients receiving less than 4 chemotherapy cycles (i.e. around 2 months of treatment) is expected to be unequal between both arms (around < 5% in the control arm and around 20% in the experimental arm). Overall, 140 patients will have to be included.

Most data from the literature are derived from retrospective or prospective non-randomized studies. Results from randomized trials are scarce, and suffer from not well defined/debatable unresectability criteria for CRLM. It is expected that most of the resection will occur within 6 months after randomization. The 30% R0-R1 resection rate in the HAI arm (experimental arm) is based on the results of three prospective single-arm HAI studies using three cytotoxic agents (fluoropyrimidine + oxaliplatin + irinotecan) and a targeted therapy (cetuximab, panitumumab, or bevacizumab in two of these studies) [27, 32, 37]. The 10% R0-R1 resection rate in the control arm is not well documented in the literature, particularly since this study will include patients with miscellaneous tumor response to prior induction sys-CT regimen(s). Conversion to complete resection after second-line sys-CT has not been prospectively assessed. Taking into account that responders to induction sys-CT will only be included if liver metastases are considered unresectable after at least 2 months of induction chemotherapy (using predefined rigorous unresectability criteria), and that response rates in the second- and later-line settings are usually less than 30%, the rate of conversion to R0-R1 resection is expected to be low (less than 10%).

Since the hypotheses are difficult to define and given the exploratory nature of this hypothesis in the control arm, we plan to monitor the CRR during the study in order to adjust the hypothesis and increase the sample size, if necessary.

**Statistical analysis plan**

The main analysis will be conducted in the “intention to treat” population defined as all randomized patients. A second per-protocol analysis in patients receiving at least 4 chemotherapy cycles in both arms following by a tumor response evaluation will be conducted. Analysis will be performed with a minimum follow-up of 1 year.

Results for the primary and secondary endpoints will be presented by arm with a confidence interval at 95% (Rothman for survival data). Safety data will be reported according to their frequency and by system organ class. The rate of patients with at least one severe toxicity (grade > 3) and at least one clinically relevant severe toxicity will be presented. For overall survival, survival rates at 12, 24, and 36 months and median will be calculated. For hepatic and overall progression-free survival, rates at 6, 12 and 24 months and median will be calculated. Competing risk approach will be used to study hepatic and extra-hepatic progressions. Main analyses will be stratified on tumor RAS/BRAF status (wild type versus RAS or BRAF mutation) using stratified logrank or Chi² test. Such analysis may be completed by multivariate analyses using logistic (in particular for the main endpoint) or Cox model, as appropriate, stratified on tumor RAS/BRAF status and adjusted on stratification factor in case of imbalance between arms and/or other prognostic factors. A sensitivity analysis without the patients with BRAF mutations will be performed if some of these patients are included. For quality of life, either change from baseline using generalized mixed model for repeated assessments or time to a clinical relevant change will be used depending of the number and pattern of data available. Decision will be taken before any analysis.

**Toxicity monitoring**

Intensity of events will be estimated according to the NCI-CTCAE classification, version 4.0 (toxicity score grade 1 to 5). Catheter-related complications will be specifically evaluated.

The decision to reduce the doses will be based on the maximum toxicity observed during the rest period. The
Dose adjustments should be based on the most significant toxicity grades. If a patient has several types of toxicity, the administered dose will be the one with the least risk for the patient. Besides the specificity of the HAI administration route managed as described above, dose adjustment criteria for usual drug-induced toxicity will be the same as those used for the systemic administration of the FOLFIRINOX regimen [38]. Provided that the abolition of the IV bolus 5-FU in the HAI arm will prevent hematologic toxicity, G (M)-CSF will not be recommended as primary prophylaxis, but will be considered for high-risk patients. If abdominal pain is observed during or after HAI oxaliplatin, verification of port-catheter by angiogram will be performed systematically before the next administration. In case of documented extrahepatic perfusion and persistent abdominal pain, upper gastrointestinal endoscopy will have to be performed looking for a gastroduodenal ulcer.

**Discussion**

Our trial is the first randomized trial aiming to validate the use of HAI chemotherapy as a salvage therapy in patients with liver-only CRLM. Given the long-term survival of patients downstaged from an initially inoperable to a resectable state (~50% for downstaged patients versus <15% in non-resected patients at 5 years) [9], increasing CRR is a reasonable objective in patients with liver-only CRLM.

Despite a reproducible significant increase in tumor response rate obtained with HAI chemotherapy, one of the reasons why most previous randomized trials using HAI FUDR or 5-FU failed to provide significant increase in OS [23] is the lack of sys-CT in the HAI arm favoring extra-hepatic progression. Since the availability of “modern” sys-CT, no randomized HAI study was further performed. The available data in the literature and the observed CRR in previous studies [31, 32, 39] in patients with unresectable CRLM who received prior sys-CT are very encouraging and suggest that it could be interesting to evaluate chemotherapy intensification with HAI oxaliplatin, in order to increase the CRR and eventually PFS and OS.

Given the high ORRs obtained with current first-line systemic regimens in patients with CRLM, the intensified therapeutic strategy combining HAI and sys-CT may not be systematically proposed in the frontline setting; nonetheless, it should be introduced relatively early in patients with insufficient tumor response after induction chemotherapy.

Catheter dysfunction and abdominal pain during infusion are the main described side-effects which can limit the feasibility of HAI oxaliplatin. Catheter dysfunction, include extra-hepatic diffusion of chemotherapy (which can often be managed by percutaneous embolization of hepatic collateral vessels) that may cause gastroduodenal ulcerations, or thrombosis of the hepatic artery/oclusion of the catheter which can be managed with careful thrombolysis. Abdominal pain during intra-arterial infusion, which seems to be a specific complication of HAI oxaliplatin can be managed with concomitant systemic analgesia.

Toxicity related to HAI chemotherapy may be prevented or managed by teams experienced in this route of chemotherapy. Our trial is conducted in carefully selected centers within the PRODIGE intergroup (UNICANCER GI, FFCD, and GERCOR). The coordinating center (Gustave Roussy) already trained many of these selected centers through dedicated workshops during the past 3 years. The workshops included HAI training courses (for oncologists, surgeons, radiologists, and nurses), live demonstrations in surgical and interventional radiology operative rooms, and interactive lectures/sessions.

Another aspect to insure the feasibility of the project is the centralized review to confirm the CRLM unresectability and other eligibility criteria before each patient inclusion.

Depending on the results obtained, this randomized Phase II study will be expanded into a Phase III study to demonstrate the superiority of a therapeutic intensified strategy based on HAI chemotherapy compared to sys-CT in patients with liver-only CRLM. If confirmed, this will have a clinically relevant impact on patient survival as well as on public health because i) CRC is one of the second most frequent cause of cancer-related death; ii) CRLM are the most frequent cause of death in patients with CRC; iii) resectability is the most important prognostic factor for overall survival in metastatic CRC.

The recruitment of patients in the SULTAN study is planned for 3 years. Currently, 11 patients have been screened and 7 of them have been randomized.

**Abbreviations**

S-FU: 5-Fluorouracil; CRC: Colorectal cancer; CRLM: Colorectal liver metastases; CRR: Complete resection rate; CT-TAP: Computed tomography of thorax, abdomen and pelvis; DoR: Depth of response; FUDR: 5-Fluorodeoxyuridine; G (M)-CSF: Granulocyte-(macrophage) colony-stimulating factor; HAI: Hepatic arterial infusion; HIV: Human immunodeficiency virus; IV: Intravenous; MRI: Magnetic resonance imaging; NCI-CTCAE: National cancer institute - common terminology criteria for adverse events; ORR: Objective response rate; OS: Overall survival; PFS: Progression-free survival; RECIST: Response evaluation criteria in solid tumors; sys-CT: Systemic chemotherapy; ULN: Upper limit of normal

**Acknowledgements**

We thank Lilian Amrein from Unicancer for English editing. Patients and families.

All the participating centers and investigational teams in France.

Data management team at Institut de Cancérologie de Montpellier.

PHRC-K-2015-2506.

**Authors’ contributions**

AB drafted the manuscript. VB drafted the manuscript and the study protocol, and coordinate the trial. AM is the statistician of the study. He participated in its design, the redaction of the protocol and revised the
manuscript, MW, CD, CL, EDB, SLS, FA, AU, VGM, DS, VP, TDB, DG, MG, and JT have been involved in the study conception and design, assisted in writing the manuscript and have given final approval of the version to be published. All authors read and approved the final manuscript.

Funding
This study is financially supported by a governmental grant from the National Institute of Cancer (INCa). The authors declare that they have no competing interests relative to this study. The National Institute of Cancer (INCa) was not involved in the design of the study and collection, analysis, interpretation of data and in writing the manuscript. This study is sponsored by UNICANCER and supported by PRODIGE group which regroups FFCD (Fédération Francophone de Cancérologie Digestive), GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie) and UNICANCER gastrointestinal group.

The manuscript was peer reviewed by the funding body and the sponsor (UNICANCER).

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
This study has received the ethical approval of the Comité de Protection des Personnes – Île de France V. No EudraCT: 2016-001493-15 (Date of approval 13th October 2017). Written informed consent will be obtained from all participants.

Consent for publication
This study does not contain individual data of person.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Department of Medical Oncology, Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif Cedex, France. 2. Department of statistics and epidemiology, Villejuif, France. 3. Centre for Research in Epidemiology and Population Health (team 2), INSERM U1018, Paris-Saclay University, Villejuif, France. 4. Department of radiology, CHU Pitié Salpétrière, Paris, France. 5. Department of radiology, CHU Pitié Salpétrière, Paris, France. 6. Department of Medical Oncology, Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif Cedex, France. 7. Department of medical oncology, Centre Eugène-Marquis, Rennes, France. 8. Department of hepatogastroenterology, Hôpital Haut Levéquie, Pessac, France. 9. Department of digestive surgery, CHP Saint Grégoire, Saint-Grégoire, France. 10. Department of medical oncology, Centre Eugène-Marquis, Rennes, France. 11. Department of digestive surgery, CHP Saint Grégoire, Saint-Grégoire, France. 12. Department of Medical Oncology, Gustave Roussy, Villejuif, France. 13. Department of medical oncology, Institut de Cancérologie de l'Ouest, Angers, France. 14. RUD Uncancer, Paris, France. 15. Department of interventional radiology, Gustave Roussy, Villejuif, France. 16. Department of Surgical Oncology, Hôpital Saint Louis, Paris, France. 17. Department of Surgical Oncology, Gustave Roussy, Villejuif, France. 18. Department of digestive surgery, Hôpital Européen Georges-Pompidou, Sorbonne Paris Cité/Paris Descartes University, Paris, France.

Received: 10 December 2019 Accepted: 23 January 2020

Published online: 30 January 2020

References
1. Manfredi S, Lepage C, Hatem C, Coameur O, Faivre J, Bouvier A-M. Epidemiology and Management of Liver Metastases from Colorectal Cancer. Ann Surg. 2006;244:254–9.
2. Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 2006;93:465–74.
3. Cummings LC, Fayer JD, Cooper GS. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer. 2007;109:718–26.
4. Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol. 1986;150:195–203.
5. Scheele J, Stangl R, Altenendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990;77:1241–6.
6. Choti MA, Sitzmann JV, Tiburi MF, Suetochtiimetha W, Rangsin R, Schulik RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–66.
7. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94:982–99.
8. Adam R, Delvat V, Pascal G, Valeaune A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstreamed by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–57 discussion 657-658.
9. Jones RP, Hamann S, Malik HZ, Fenwick SW, Poston GJ, Folprecht G. Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. Eur J Cancer. 2014;50:1590–601.
10. Adam R, Aloia T, Lévi F, Wicherts DA, de Haas RJ, Paule B, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol. 2007;25:4593–602.
11. Gruenberger T, Bridgewater J, Chau I, García Alfonso P, Rivoire M, Mudan S, et al. Bevacizumab plus mFOLFOX6 or FOLFIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015;26:702–8.
12. Ye Y, Liu T-S, Ren L, Wei Y, Zhu D-X, Zai S-Y, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013;31:1931–8.
13. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culmame N, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg. 1987;206:685–93.
14. Kemény N, Daly J, Reichmann B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluoredoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med. 1987;107:495–6.
15. Hohn DC, Stagg RJ, Friedman MA, Hannigan JF, Rayner A, Ignoffo RJ, et al. A randomized trial of continuous intravenous versus hepatic intraarterial fluorouracil in patients with colorectal cancer metastatic to the liver: the northern California oncology group trial. J Clin Oncol. 1989;7:1646–54.
16. Martin JK, O’Connell MJ, Weand HS, Fitzgibbons RJ, Maillard JA, Rubin J, et al. Intra-arterial fluorouracil vs systemic fluorouracil for hepatic metastases from colorectal cancer: A randomized trial. Arch Surg. 1990;125:1022–7.
17. Rougier P, Laplanche A, Huguer M, Hay JM, Ollivier JM, Escht J, et al. Hepatic arterial infusion of fluorouracil in patients with liver metastases from colorectal cancer: long-term results of a prospective randomized trial. J Clin Oncol. 1992;10:1112–8.
18. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery fluorouracil infusion for colorectal liver metastases. Lancet. 1994;344:1255–60.
19. Lorenz M, Müller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2000;18:243–54.
20. Kerr DJ, McAdle CJ, Ledermann J, Taylor I, Sherlock DJ, Schlag PM, et al. Intraperitoneal arterial versus intravenous fluorouracil and folinic acid for colorectal liver metastases: a multicentre randomised trial. Lancet. 2003;361:366–73.
21. Kemény NE, Niedzwiecki D, Hollis DR, Lenz H-J, Warren RS, Naughton MJ, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 89411). J Clin Oncol. 2006;24:1395–403.
22. Mocellin S, Pasquall S, Nitti D. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. Cochrane Database Syst Rev. 2009;3:CD007823.
23. Ammiri JB, Kemény NE. Regional hepatic chemotherapies in treatment of colorectal cancer metastases to the liver. Semin Oncol. 2010;37:139–48.
24. Kingham TP, D’Angelica M, Kemény NE. Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases. J Surg Oncol. 2010;102:988–95.

Page 10 of 11

Boilève et al. BMC Cancer (2020) 20:74
25. Kelly RJ, Kemeny NE, Leonard GD. Current strategies using hepatic arterial infusion chemotherapy for the treatment of colorectal cancer. Clin Colorectal Cancer. 2005;5:166–74.
26. Kemeny NE, Melendez FDH, Caparu M, Paty PB, Fong Y, Schwartz LH, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27:3465–71.
27. Gallagher DJ, Caparu M, Raggio G, Kemeny N. Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. Ann Oncol. 2007;18:1995–9.
28. Dzodic R, Gomez-Abuin G, Rougier P, Bonnay M, Ardouin P, Gouyette A, et al. Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model. Anti-Cancer Drugs. 2004;15:647–50.
29. Guthoff J, Lotspeich E, Fester C, Wallin I, Schatz M, Ehrlsson H, et al. Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folic acid and mitomycin C. oxaliplatin pharmacokinetics and feasibility. Anticancer Res. 2003;23:5203–8.
30. Boige V, Malka D, Elias D, Castaing M, De Baere T, Goere D, et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol. 2008;15:219–26.
31. Goéré D, Deshaies I, de Baere T, Boige V, Malka D, Dumont F, et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg. 2010;251:686–91.
32. Levi F, Ducrèux M, Smith DM, Hebbard M, Lepère C, Focan CNJ, et al. Four-year survival in patients (pts) undergoing liver surgery after neoadjuvant triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) for previously treated and unresectable liver metastases from kras wt colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228). J Clin Oncol. 2014;32(15_suppl):3589.
33. Deschamps F, Rao P, Teritehau C, Hakime A, Malka D, Boige V, et al. Percutaneous femoral implantation of an arterial port catheter for intraarterial chemotherapy: feasibility and predictive factors of long-term functionality. J Vasc Interv Radiol. 2010;21:1681–8.
34. Deschamps F, Elias D, Goere D, Malka D, Ducrèux M, Boige V, et al. Intra-arterial hepatic chemotherapy: a comparison of percutaneous versus surgical implantation of port-catheters. Cardiovasc Intervent Radiol. 2011;34:973–9.
35. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii1–9.
36. Philip JM, Tougeron D, Léonard D, Benhaim L, Desouleux G, Dupré A, et al. Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFOD, SFRQ, SFR). Dig Liver Dis. 2019;51:1357–63.
37. D’Angelica M, Corea-Gallego C, Paty PB, Cernek A, Gewirtz AN, Chou JY, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg. 2015;261:353–60.
38. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécoauam Y, et al. FOLFRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.
39. Ducrèux M, Ychou M, Laplanche A, Garnelin E, Lasser P, Hussein F, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005;23:4881–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.